Related Experiment Video
Updated: Sep 27, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Importance of Early Next-Generation Sequencing in Microsatellite Unstable Colon Cancer With a High Tumor Mutation
1Medical Oncology, Allegheny Health Network, Pittsburgh, USA.
Abstract:
Colon cancer is one of the leading causes of cancer-related deaths. Microsatellite instability (MSI) or deficient mismatch repair proteins with a high tumor mutation burden (TMB) colon cancer are less responsive to chemotherapy. Targeted therapies based on early next-generation sequencing (NGS) in metastatic colon cancer can help significantly in overall prognosis. Here, we report a case of colon cancer that illustrated significant TMB and MSI and responded poorly to treatment due to delay in NGS testing.
Insights
High tumor mutation burden (TMB) and microsatellite instability (MSI) in colon cancer reduce chemotherapy effectiveness. Early next-generation sequencing (NGS) is crucial for timely targeted therapy, improving patient outcomes.
Area of Science:
- Oncology
- Genomics
Background:
- Colon cancer is a leading cause of cancer mortality.
- Microsatellite instability (MSI) or deficient mismatch repair proteins and high tumor mutation burden (TMB) are associated with poor response to chemotherapy in colon cancer.
Observation:
- This case report details a patient with colon cancer exhibiting high TMB and MSI.
- The patient's colon cancer responded poorly to initial treatment.
Findings:
- A delay in obtaining next-generation sequencing (NGS) results impacted treatment decisions.
- Early NGS testing in metastatic colon cancer is vital for identifying actionable mutations.
Implications:
- Timely NGS testing can significantly improve the overall prognosis for patients with metastatic colon cancer.
- Personalized treatment strategies based on genomic profiling are essential for managing complex colon cancer cases.

